Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

14.75
-0.0310-0.21%
Post-market: 14.08-0.6700-4.54%19:59 EST
Volume:7.96M
Turnover:123.59M
Market Cap:2.28B
PE:- -
High:15.93
Open:14.58
Low:13.06
Close:14.78
52wk High:15.93
52wk Low:13.06
Shares:154.74M
Float Shares:132.00M
Volume Ratio:1.25
T/O Rate:6.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.9715
ROE:-43.98%
ROA:-26.47%
PB:1.35
PE(LYR):-2.97

Loading ...

Novartis sees sales boost from key cancer drugs

Reuters
·
Nov 20, 2025

Novartis Forecasts 2025-2030 Sales CAGR Of +5-6% CC

Reuters
·
Nov 20, 2025

BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44

Reuters
·
Nov 19, 2025

Avidity Biosciences Inc - Plans Bla Submission for Del-Zota in 2026

THOMSON REUTERS
·
Nov 19, 2025

BAIJIN LIFE SCI (01466) Subsidiary Plans to Invest in YouHuan Bio to Build a Globally Leading circRNA Technology R&D Platform

Stock News
·
Nov 19, 2025

Baijin Life Science Enters Strategic Partnership to Advance RNA Technology

TIPRANKS
·
Nov 19, 2025

Mirxes Partners with Walvax to Advance RNA-Centric Precision Medicine

TIPRANKS
·
Nov 18, 2025

MIRXES-B (02629) Signs MOU with Watson to Establish RNA-Centric Preventive and Precision Medicine Platform

Stock News
·
Nov 18, 2025

Circio Holding ASA to Present Latest circVec RNA Platform Results in Upcoming Webcast

TIPRANKS
·
Nov 17, 2025

Hold Rating on Avidity Biosciences Amid Novartis Acquisition and Strategic Developments

TIPRANKS
·
Nov 12, 2025

Chardan Capital Reaffirms Their Hold Rating on Avidity Biosciences (RNA)

TIPRANKS
·
Nov 12, 2025

Wave Life Sciences: Advancements in RNA Medicines Strengthen Buy Rating

TIPRANKS
·
Nov 11, 2025

Avidity Biosciences Is Maintained at Neutral by Chardan Capital

Dow Jones
·
Nov 11, 2025

Hold Rating on Avidity Biosciences Amid Novartis Acquisition Uncertainty

TIPRANKS
·
Nov 11, 2025

Avidity Biosciences Reports Increased Revenue Amid Losses

TIPRANKS
·
Nov 11, 2025

Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate

Benzinga
·
Nov 11, 2025

Avidity Biosciences reports wider-than-expected Q3 net loss

Reuters
·
Nov 11, 2025

SanegeneBio announces RNAi licensing, collaboration with Lilly

TIPRANKS
·
Nov 10, 2025

Wave Life Sciences to Present at Upcoming Investor Conferences

GlobeNewswire
·
Nov 07, 2025

Chardan Downgrades Avidity Biosciences to Neutral From Buy

MT Newswires Live
·
Nov 07, 2025